Inline quality assurance in medical technology

Anyone who looks for defects only at the end of the line finds them too late. In medical technology, quality control is therefore increasingly moving directly into the production line, driven by regulation, rising unit numbers, and Artificial Intelligence.

In medical technology, the smallest defect often makes the difference. A scratch, a trapped particle, a burr, or a micro-hole is not merely a cosmetic flaw here: such defects can impair function, create a hygiene risk, or, in the worst case, jeopardize regulatory approval. That is exactly why a question long treated as secondary is now moving to the forefront: when and where in production testing takes place.

Traditionally, testing happens at the end: the finished product comes off the line, and inspection follows. Inline quality control reverses this sequence. Instead of waiting until the end of the production cycle, it integrates testing continuously into the production line, at multiple points in the process. Sensors and automated systems detect deviations in real time, whether in dimensions, color, defective parts, or mechanical faults. This allows problems with material, process, or machine to be identified early, not only once an entire batch is complete.

The distinction sounds technical, but it is strategic. A defect found only at the end has already been paid for through every step of manufacturing. A defect found during production allows for correction before significant scrap accumulates. The comparison below summarizes how the two approaches differ.

Regulations such as the MDR, together with the standards ISO 13485 and ISO 14971, place high demands on medical device manufacturers, covering everything from end-to-end traceability and documentation to risk management across the entire product life cycle. Testing processes must be traceable, validatable, and auditable. Automated inline systems capture relevant process parameters, such as torque, joining forces, test results, and serial numbers, automatically and in real time. Testing thus generates a dataset that supports documentation and secures conformity from the outset, rather than compiling it retroactively.

The second factor is the need to scale. Unit volumes and product variety are increasing, and this is precisely where manual visual inspection reaches its limits, especially as quantities grow and complexity rises. Integrated, automated inspection offers scalability here, reduces scrap and recall risk, and at the same time relieves pressure on scarce skilled personnel.

Conventional machine vision is not sufficient everywhere. One example is the extrusion of tubing, as used among other things in medical technology. High speeds, changing surface reflections, rotation, and varying diameters make consistent optical inspection demanding. Fine defects such as bubbles, streaks, or micro-holes must be reliably detected, without reflections or dust generating unnecessary false rejects.

This is where Artificial Intelligence comes in. AI-based systems recognize complex defect patterns and improve both the accuracy and the speed of inspection. Combined with matched camera technology, well-designed lighting concepts, and algorithms trained on the specific component, this produces inspection solutions that integrate seamlessly into existing manufacturing processes.

In practice, inline inspection has arrived further than current awareness levels suggest. Suppliers already carry out a wide range of inline quality checks directly in the cleanroom, taking samples in parallel with production to detect disturbances in machinery or tooling early, before they affect product quality. This is complemented by optical and tactile measurement methods such as torque testing, 3D coordinate measurement, and structured light sensing.

Inspection is also firmly embedded in the manufacturing flow in automated assembly. Leak tests confirm component tightness, camera measurements check position and gap dimensions, presence checks confirm that all parts have been correctly installed, and functional tests verify actual performance, for example a spray test to check dosing in inhalers. Such integrated tests reduce rework, lower the scrap rate, and create a solid basis for regulatory quality assurance.

Inline quality assurance is not purely a matter of efficiency. It shifts the point at which inspection takes place forward in time. In doing so, it shifts where quality is created: no longer in the final inspection, but continuously throughout the process. For MedTech suppliers and contract manufacturers, three advantages come together:

• Early defect detection lowers the cost of scrap.
• Automatic data capture simplifies proof of compliance with the MDR and similar regulations.
• Scalability keeps pace with rising unit volumes.

Those who inspect only at the end of the line find out late, and expensively, what went wrong. Those who inspect on the production line know immediately.